UY39150A - Pirrolopirimidinaminas como inhibidores del sistema del complemento - Google Patents
Pirrolopirimidinaminas como inhibidores del sistema del complementoInfo
- Publication number
- UY39150A UY39150A UY0001039150A UY39150A UY39150A UY 39150 A UY39150 A UY 39150A UY 0001039150 A UY0001039150 A UY 0001039150A UY 39150 A UY39150 A UY 39150A UY 39150 A UY39150 A UY 39150A
- Authority
- UY
- Uruguay
- Prior art keywords
- complement system
- inhibitors
- pyrrolopyrimidinamines
- compounds
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos de Fórmula (I) y sus sales farmacéuticamente aceptables, que son inhibidores del sistema del complemento. También, composiciones farmacéuticas que comprenden un compuesto con dichas características y métodos para usar los compuestos y composiciones en el tratamiento o la prevención de una enfermedad o condición caracterizada por una actividad aberrante del sistema del complemento.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063004799P | 2020-04-03 | 2020-04-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY39150A true UY39150A (es) | 2021-10-29 |
Family
ID=77929437
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001039150A UY39150A (es) | 2020-04-03 | 2021-04-05 | Pirrolopirimidinaminas como inhibidores del sistema del complemento |
Country Status (22)
Country | Link |
---|---|
US (1) | US20230159536A1 (es) |
EP (1) | EP4125914A4 (es) |
JP (1) | JP2023519824A (es) |
KR (1) | KR20220163955A (es) |
CN (1) | CN115427044A (es) |
AR (1) | AR121715A1 (es) |
AU (1) | AU2021246098A1 (es) |
BR (1) | BR112022018067A2 (es) |
CA (1) | CA3176808A1 (es) |
CL (1) | CL2022002649A1 (es) |
CO (1) | CO2022015630A2 (es) |
CR (1) | CR20220553A (es) |
CU (1) | CU20220060A7 (es) |
DO (1) | DOP2022000211A (es) |
EC (1) | ECSP22085221A (es) |
IL (1) | IL296978A (es) |
JO (1) | JOP20220227A1 (es) |
MX (1) | MX2022012056A (es) |
PE (1) | PE20230601A1 (es) |
TW (1) | TW202204358A (es) |
UY (1) | UY39150A (es) |
WO (1) | WO2021202977A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023069301A1 (en) * | 2021-10-18 | 2023-04-27 | Alexion Pharmaceuticals, Inc. | Use of complement factor d inhibitor for treatment of lupus nephritis and immunoglobulin a nephropathy |
WO2024008121A1 (zh) * | 2022-07-06 | 2024-01-11 | 南京明德新药研发有限公司 | 二氟取代的氮杂双环化合物及其应用 |
WO2024047078A1 (en) * | 2022-09-01 | 2024-03-07 | F. Hoffmann-La Roche Ag | Dosage regimen of vicasinabin |
US11945818B1 (en) | 2023-09-06 | 2024-04-02 | King Faisal University | Pyrrolo[3,2-c]quinoline compounds as CK2 inhibitors |
US11964981B1 (en) | 2023-09-18 | 2024-04-23 | King Faisal University | Substituted pyrimido[4,5-b]indoles as CK2 inhibitors |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL123986A (en) * | 1997-04-24 | 2011-10-31 | Organon Nv | Medicinal compounds |
CA2823665A1 (en) * | 2011-01-04 | 2012-07-12 | Novartis Ag | Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd) |
-
2021
- 2021-03-31 AR ARP210100817A patent/AR121715A1/es unknown
- 2021-04-01 TW TW110112139A patent/TW202204358A/zh unknown
- 2021-04-02 PE PE2022002121A patent/PE20230601A1/es unknown
- 2021-04-02 BR BR112022018067A patent/BR112022018067A2/pt unknown
- 2021-04-02 WO PCT/US2021/025547 patent/WO2021202977A1/en active Application Filing
- 2021-04-02 MX MX2022012056A patent/MX2022012056A/es unknown
- 2021-04-02 US US17/915,179 patent/US20230159536A1/en active Pending
- 2021-04-02 EP EP21781014.2A patent/EP4125914A4/en active Pending
- 2021-04-02 CU CU2022000060A patent/CU20220060A7/es unknown
- 2021-04-02 CN CN202180025930.0A patent/CN115427044A/zh active Pending
- 2021-04-02 IL IL296978A patent/IL296978A/en unknown
- 2021-04-02 CA CA3176808A patent/CA3176808A1/en active Pending
- 2021-04-02 AU AU2021246098A patent/AU2021246098A1/en active Pending
- 2021-04-02 KR KR1020227033595A patent/KR20220163955A/ko active Search and Examination
- 2021-04-02 JP JP2022556491A patent/JP2023519824A/ja active Pending
- 2021-04-02 JO JOP/2022/0227A patent/JOP20220227A1/ar unknown
- 2021-04-02 CR CR20220553A patent/CR20220553A/es unknown
- 2021-04-05 UY UY0001039150A patent/UY39150A/es unknown
-
2022
- 2022-09-28 CL CL2022002649A patent/CL2022002649A1/es unknown
- 2022-09-28 DO DO2022000211A patent/DOP2022000211A/es unknown
- 2022-10-31 CO CONC2022/0015630A patent/CO2022015630A2/es unknown
- 2022-11-02 EC ECSENADI202285221A patent/ECSP22085221A/es unknown
Also Published As
Publication number | Publication date |
---|---|
DOP2022000211A (es) | 2022-11-15 |
IL296978A (en) | 2022-12-01 |
WO2021202977A1 (en) | 2021-10-07 |
TW202204358A (zh) | 2022-02-01 |
CN115427044A (zh) | 2022-12-02 |
MX2022012056A (es) | 2022-10-13 |
ECSP22085221A (es) | 2022-12-30 |
JP2023519824A (ja) | 2023-05-15 |
JOP20220227A1 (ar) | 2023-01-30 |
CL2022002649A1 (es) | 2023-05-26 |
PE20230601A1 (es) | 2023-04-10 |
KR20220163955A (ko) | 2022-12-12 |
US20230159536A1 (en) | 2023-05-25 |
EP4125914A4 (en) | 2024-07-03 |
AR121715A1 (es) | 2022-06-29 |
CU20220060A7 (es) | 2023-05-11 |
EP4125914A1 (en) | 2023-02-08 |
CR20220553A (es) | 2023-02-03 |
BR112022018067A2 (pt) | 2022-10-25 |
AU2021246098A1 (en) | 2022-10-20 |
CO2022015630A2 (es) | 2022-11-29 |
CA3176808A1 (en) | 2021-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY39150A (es) | Pirrolopirimidinaminas como inhibidores del sistema del complemento | |
UY38174A (es) | Benzofurano, benzopirrol, benzotiofeno sustituidos y otros compuestos relacionados, como inhibidores del complemento | |
CO2022016323A2 (es) | Derivados de triazina que tienen actividad inhibidora de la replicación del virus y composición farmacéutica que constituye el mismo | |
DOP2022000124A (es) | Derivados de pirazolilo útiles como agentes anticancerígenos | |
UY38196A (es) | Inhibidores de cinasa dependientes de ciclina | |
CO2018008916A2 (es) | Compuestos de benzopirazol y análogos de estos | |
CU20160109A7 (es) | Compuestos de indazol como inhibidores de irak4 | |
UY35617A (es) | Inhibidores de la fosfatidilinositol 3-quinasa | |
CL2022000257A1 (es) | Regímenes de dosificación para inhibidores orales del factor d del complemento | |
SV2018005633A (es) | Derivados de heteroarilo como inhibidores de parp | |
CL2022000875A1 (es) | Inhibidores del factor d del complemento para administración oral | |
ECSP088676A (es) | Pirazolquinolonas como potentes inhibidores de parp | |
AR079208A2 (es) | Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica | |
DOP2021000077A (es) | Derivados de quinolina como inhibidores de la integrina alfa4beta7 | |
CO2019010559A2 (es) | Composiciones y compuestos terapéuticos y métodos para utilizarlos | |
CO2022005926A2 (es) | Inhibidores del factor d del complemento para administración oral | |
CU20160166A7 (es) | Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1 | |
CL2021000329A1 (es) | Compuestos útiles en terapia del vih | |
CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
AR128500A1 (es) | Inhibidores de arn helicasa dhx9 y usos de los mismos | |
ECSP23088732A (es) | Moduladores de trex1 | |
AR119548A1 (es) | Regímenes de dosificación para inhibidores orales del factor d del complemento | |
AR126892A1 (es) | Compuestos de aminopiridina sustituidos como inhibidores de egfr | |
AR110317A1 (es) | Compuestos de ácido ascórbico y quinona para tratar enfermedad de chagas |